Other studies have confirmed that glibenclamide and metformin, both of which are typical treatments for diabetes, have the potential to inhibit the activation of the NLRP3 inflammasome, indirectly indicating that the NLRP3 inflammasome is associated with T1DM. This evidence concerns the gene NLRP3 and type 1 diabetes mellitus.